The Critical Edge Podcast

Targeted Hemostasis in the SICU

Listen Later

This episode is an overview of coagulation disorders and their management within surgical and intensive care settings. It examines the distinction between congenital conditions, such as hemophilia and von Willebrand disease, and acquired defects stemming from trauma, sepsis, or organ failure. The authors highlight how physiological stressors like acidosis and hypothermia exacerbate bleeding, while also addressing the complexities of anticoagulant reversal. Modern diagnostic tools, including thromboelastography, are presented alongside therapeutic strategies involving blood component therapy and pharmacological interventions like tranexamic acid. Ultimately, the source emphasizes a systematic clinical approach to stabilizing patients by balancing rapid hemorrhage control with precise hematologic support.

 

 

The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns.

 

 

 

Targeted Hemostasis in the SICU
This guide synthesizes critical information regarding the pathophysiology, diagnosis, and management of bleeding and coagulation disorders encountered in surgical and trauma intensive care settings.
 
I. Historical Context and Evolution of Therapy
The effective management of hemorrhage is a relatively modern development in medical history. Key milestones include:
  • Discovery of Blood Types: Karl Landsteiner identified types A, B, and O in 1900, followed by Decastello and Sturli identifying type AB in 1902.
  • Establishment of Blood Banking: The first blood bank in the United States was established in 1937.
  • Technological Advances: The development of crossmatching, anticoagulation, storage techniques, plastic bags, and plasmapheresis eventually enabled component therapy, allowing for the targeted replacement of specific blood elements.
    • II. Congenital Bleeding Disorders
    Von Willebrand Disease (vWD)
    As the most common inherited bleeding disorder, vWD results from a deficiency or dysfunction of von Willebrand factor (vWF), which is essential for platelet adhesion and factor VIII stabilization.
    • Type 1: A quantitative deficiency of vWF.
    • Type 2 (2a and 2b): Qualitative functional defects in vWF.
    • Type 3: Complete absence of vWF.
    • Diagnosis: Supported by prolonged partial thromboplastin time (PTT), reduced vWF antigen (in Types 1 and 3), and abnormal ristocetin cofactor assays.
    • Therapy:
      • DDAVP: Stimulates vWF/Factor VIII release; used in Type 1 and 2a; contraindicated in Type 2b.
      • Factor VIII vWF Concentrates: Preferred for Types 2 and 3, or non-responsive Type 1.
      • Cryoprecipitate: Third-line therapy due to lack of virus inactivation.
      • Adjuvants: Antifibrinolytic amino acids (aminocaproic acid and tranexamic acid).
        • Hemophilia A and B
        Both are X-linked disorders primarily expressed in males.
        • Hemophilia A (Factor VIII Deficiency): Clinical severity is linked to factor levels: mild (>30%), moderate (1%–5%), and severe (<1%). Treatment involves recombinant factor VIII. Recombinant activated factor VIIa (rFVIIa) is used if the patient develops "inhibitors" (IgG antibodies).
        • Hemophilia B (Factor IX Deficiency/Christmas Disease): Clinically similar to Hemophilia A. Treatment utilizes recombinant factor IX concentrates. Inhibitor development is less common (1%) than in Hemophilia A.
          • III. Acquired Bleeding Disorders in the ICU
          Coagulopathy of Trauma
          This condition results from a complex interaction between hemorrhagic shock and tissue injury. Tissue ischemia and injury trigger systemic anticoagulation and hyperfibrinolysis via the activation of protein C and the release of tissue plasminogen activator (tPA). Resuscitation efforts can exacerbate this through dilution, acidosis, and hypothermia.
           
          Disseminated Intravascular Coagulation (DIC)
          DIC is a syndrome of systemic intravascular activation of coagulation resulting in fibrin deposition in the microvasculature.
          • Primary Causes: Sepsis (most common), trauma, malignancy, and liver failure.
          • Phenotypes: It may manifest as a thrombotic disorder (common in sepsis) or a consumptive bleeding disorder (fulminant DIC).
          • Diagnosis: The International Society on Thrombosis and Haemostasis (ISTH) scoring system uses platelet count, fibrin markers (D-dimer), PT prolongation, and fibrinogen levels. D-dimer is the most sensitive test.
          • Treatment: Focuses on addressing the underlying disease. FFP and platelets are used for active bleeding.
            • Heparin-Induced Thrombocytopenia (HIT)
            HIT is an immune-mediated reaction (IgG antibodies to platelet factor IV complex) that causes paradoxical thrombosis rather than bleeding.
            • Clinical Signs: Venous or arterial thromboses (pathognomonic "white clots") and skin necrosis.
            • Diagnosis: Assessment via the 4Ts score or HEP score, followed by ELISA (to rule out) and Serotonin Release Assay (SRA) to confirm.
            • Management: Immediate cessation of all heparin. Empiric treatment with direct thrombin inhibitors (argatroban, lepirudin) or fondaparinux.
              • Liver and Renal Disease
              • End-Stage Liver Disease (ESLD): Characterized by impaired synthesis of coagulation factors, thrombocytopenia, and enhanced fibrinolysis. Despite high INR, patients may be in a procoagulant state because natural anticoagulants (Proteins C and S) are also reduced while Factor VIII (produced by endothelium) remains high.
              • Renal Failure: Uremia causes platelet dysfunction (impaired adhesion and aggregation). Hemodialysis is the most effective therapy for this dysfunction, though DDAVP can be used for acute bleeding.
                • COVID-19-Associated Coagulopathy
                Severe COVID-19 often induces a hypercoagulable state characterized by high D-dimer levels and increased risk of venous and arterial thrombosis. Management typically involves tiered venous thromboembolism (VTE) prophylaxis based on D-dimer levels.
                 
                IV. Physiological Contributors to Coagulopathy
                Hypothermia
                Temperatures below 34°C impair coagulation enzyme activity and platelet function (adhesion and aggregation). At temperatures below 32°C, mortality in trauma patients approaches 100%. Treatment requires aggressive core rewarming (warm fluids, humidified air, or continuous arteriovenous rewarming).
                 
                Acidosis
                Severe metabolic acidosis (pH < 7.1) decreases the rate of thrombin generation. Treatment must target the underlying cause (e.g., fluid resuscitation for lactic acidosis) rather than just the pH level; sodium bicarbonate is generally not recommended for lactic acidosis.
                 
                V. Diagnostic Evaluation and Laboratory Testing
                Clinical Evaluation
                The primary objective is to differentiate surgical bleeding (requiring reoperation) from nonsurgical coagulopathic bleeding (requiring medical management).
                 
                Essential Laboratory Tests
                • Prothrombin Time (PT) and INR: Measures the extrinsic and common pathways; used to monitor warfarin.
                • Partial Thromboplastin Time (PTT): Measures the intrinsic and common pathways; monitors heparin.
                • Platelet Function Assays: Includes the PFA-100 and VerifyNow (for P2Y12 inhibition).
                • Thromboelastography (TEG) and ROTEM: Viscoelastic tests that provide a real-time graph of clot formation, strength, and lysis. These are highly effective for guiding resuscitation in massive transfusion scenarios.
                • Thrombin Time (TT): Sensitive to fibrinogen levels and the presence of heparin.
                • D-dimer and FSPs: Specific markers for fibrinolysis and DIC.
                  • VI. Management and Pharmacologic Reversal
                  Transfusion Therapy
                  • Fresh Frozen Plasma (FFP): Contains all clotting factors. Indicated for bleeding with PT/PTT > 1.5 times normal or emergent warfarin reversal.
                  • Platelets: Transfused for counts < 10,000/mm³ (spontaneous risk) or higher thresholds (50,000–100,000/mm³) for surgery. Single-donor apheresis platelets are preferred to reduce immune sensitization.
                  • Cryoprecipitate: Used to replace fibrinogen when levels fall below 100 mg/dL.
                    • Pharmacologic Agents
                    • Tranexamic Acid (TXA): An antifibrinolytic. In trauma (CRASH-2 trial), it must be administered within 3 hours of injury to reduce mortality; it is contraindicated if started after 8 hours.
                    • Desmopressin (DDAVP): Used for vWD, renal failure-associated platelet dysfunction, and to counteract antiplatelet drugs in TBI.
                    • Recombinant Factor VIIa (rFVIIa): Originally used for hemophilia with inhibitors; now used sparingly in trauma due to high cost and thrombotic risks.
                      • Reversal of Anticoagulants
                      • Warfarin: Reversed using Vitamin K (slow), FFP (moderate), or 4-factor Prothrombin Complex Concentrate (PCC) for rapid, low-volume reversal.
                      • Heparin: Reversed with Protamine Sulfate (1 mg per 100 units of heparin).
                      • Direct Oral Anticoagulants (DOACs):
                        • Dabigatran (Direct Thrombin Inhibitor): Reversed by Idarucizumab.
                        • Factor Xa Inhibitors (Apixaban, Rivaroxaban): Reversed by Andexanet Alpha or 4-factor PCC.
                          • VII. Glossary of Key Terms
                          • 4Ts Score: A clinical prediction rule used to determine the probability of Heparin-Induced Thrombocytopenia based on Thrombocytopenia, Timing, Thrombosis, and other causes.
                          • Andexanet Alpha: A recombinant protein that acts as a decoy to bind and sequester factor Xa inhibitors.
                          • Cryoprecipitate: A concentrated blood component containing fibrinogen, vWF, and factor VIII.
                          • D-dimer: A specific fibrin split product used as a sensitive marker for DIC and thrombosis.
                          • DDAVP (Desmopressin): A synthetic analogue of vasopressin that triggers the release of vWF and factor VIII from the endothelium.
                          • Idarucizumab: A monoclonal antibody fragment designed specifically to reverse the effects of dabigatran.
                          • PCC (Prothrombin Complex Concentrate): A concentrate containing vitamin K-dependent factors (II, VII, IX, X) used for rapid warfarin reversal.
                          • Ristocetin Cofactor Assay: A laboratory test measuring the ability of vWF to induce platelet aggregation.
                          • Thromboelastography (TEG): A point-of-care test that assesses the viscoelastic properties of whole blood as it clots.
                          • White Clot: A pathognomonic arterial thrombosis composed of platelet plugs, specifically associated with HIT.
                            • ...more
                            View all episodesView all episodes
                            Download on the App Store
                            The Critical Edge PodcastBy The Critical Edge